

08/690,775




FIGURE 1A




FIGURE 1B




FIGURE 1C

| | |
|-----------|----------------|
| APPROVED | O.G. FIG. |
| | CLASS SUBCLASS |
| BY | 424 145-1 |
| DRAFTSMAN | |

08/690,775

1 mg/kg




FIGURE 2A

3 mg/kg




FIGURE 2B

10 mg/kg





FIGURE 2C

| | | |
|----------|-----------|----------|
| APPROVED | O.G. FIG. | |
| | CLASS | SUBCLASS |
| BY | DRAFTSMAN | |

08/690,775

Physician's Global Disease Assessment
(VAS - 0-10 cm)

1 mg/kg



○ cA2 - MTX-
● cA2 - MTX+
□ Placebo - MTX+


Weeks

(n), cA2 - MTX-
(n), cA2 - MTX+
(n), Placebo - MTX+

FIGURE 3A

Physician's Global Disease Assessment
(VAS - 0-10 cm)

3 mg/kg



○ cA2 - MTX-
● cA2 - MTX+


Weeks

(n), cA2 - MTX-
(n), cA2 - MTX+

FIGURE 3B

Physician's Global Disease Assessment
(VAS - 0-10 cm)

10 mg/kg



○ cA2 - MTX-
● cA2 - MTX+

Weeks

(n), cA2 - MTX-
(n), cA2 - MTX+


FIGURE 3C

| | | |
|-----------|-----------|----------|
| APPROVED | O.G. FIG. | |
| | CLASS | SUBCLASS |
| BY | | |
| DRAFTSMAN | | |

| | | |
|-----------|-----------|----------|
| APPROVED | O.G. FIG. | |
| | CLASS | SUBCLASS |
| BY | | |
| DRAFTSMAN | | |

Patient Disease Assessment
(VAS - 0-10 cm)

1 mg/kg




—○— cA2 - MTX-
—●— cA2 - MTX+
—□— Placebo - MTX+

Weeks
(n), cA2 - MTX-
(n), cA2 - MTX+
(n), Placebo - MTX+

FIGURE 4A

Patient Disease Assessment
(VAS - 0-10 cm)

3 mg/kg




—○— cA2 - MTX-
—●— cA2 - MTX+

Weeks
(n), cA2 - MTX-
(n), cA2 - MTX+

FIGURE 4B

Patient Disease Assessment
(VAS - 0-10 cm)

10 mg/kg



—○— cA2 - MTX-
—●— cA2 - MTX+

Weeks
(n), cA2 - MTX-
(n), cA2 - MTX+

FIGURE 4C

08/690,775

1 mg/kg




FIGURE 5A

3 mg/kg




FIGURE 5B

10 mg/kg




FIGURE 5C

| | | |
|-----------|-----------|----------|
| APPROVED | O.G. FIG. | |
| | CLASS | SUBCLASS |
| BY | | |
| DRAFTSMAN | | |

08/690,775




FIGURE 6A




FIGURE 6B




FIGURE 6C

| | | |
|-----------|-----------|----------|
| APPROVED | O.G. FIG. | SUBCLASS |
| | CLASS | |
| BY | | |
| DRAFTSMAN | | |

08/1690, 775

CA2, no methotrexate

1 mg/kg cA2 + methotrexate

cA2 IgG ($\mu\text{g/mL}$)

FIGURE 7A

1 mg/kg cA2, no methotrexate

cA2 IgG ($\mu\text{g/mL}$)

FIGURE 7B

3 mg/kg cA2 + methotrexate

cA2 IgG ($\mu\text{g/mL}$)

FIGURE 7C

3 mg/kg cA2, no methotrexate

cA2 IgG ($\mu\text{g/mL}$)

FIGURE 7D

10 mg/kg cA2 + methotrexate

cA2 IgG ($\mu\text{g/mL}$)

Infusions: ↑ ↑ ↑ ↑ ↑ ↑ ↑

Weeks Post Infusion #1

FIGURE 7E

10 mg/kg cA2, no methotrexate

cA2 IgG ($\mu\text{g/mL}$)

Infusions: ↑ ↑ ↑ ↑ ↑

Weeks Post Infusion #1

FIGURE 7F

08/690,775

| | | |
|-----------|-----------|----------|
| APPROVED | O.G. FIG. | |
| | CLASS | SUBCLASS |
| BY | | |
| DRAFTSMAN | | |




FIGURE 8A




FIGURE 8B